Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Continues With Growth Strategy Implementation 0 comments
    Apr 19, 2013 2:19 PM | about stocks: CXM

    When Cardium Therapeutics recently released their 2012 financial results, reflecting the company's extensive investment required for the important introduction of Excellagen and nutraceutical initiatives, and the initiation of their Generx ASPIRE clinical study, the standout feature of the report was the extensive list of achievements put in place to drive Cardium's long-term growth strategy.

    Cardium is actively advancing its Generx DNA-based angiogenic growth factor therapeutic, a one-of-a-kind treatment for heart blood flow problems which, unlike other treatments, actually stimulates blood vessel growth in the heart. Closer to market is the company's Excellagen wound treatment product, which will eventually help support the Generx program. Cardium's nutraceutical initiatives, centered around the company's recent acquisition of To Go Brands, are already providing the significant source of income.

    Relating to Generx, the report indicated that Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods. The company made a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum held in Washington, DC, and has also received a favorable patent decision in Europe, along with a successful resolution of a competition over rights to key methods for the application of cardiovascular gene therapy in the treatment of coronary heart disease.

    The report also highlighted a number of accomplishments related to Cardium's continuing progress in the commercialization of its FDA-cleared Excellagen product, a wound treatment gel that has been shown to significantly improve healing for many types of wounds. Cardium has now entered into a logistics and cold chain services agreement with Smith Medical Partners, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations.

    Separately, Cardium has now established a strong foothold in the revenue-generating nutraceutical industry, through its successful acquisition of To Go Brands nutraceutical supplement platform, with over 25 products being developed and sold through established regional and national food, drug, and mass channel retailers at over 10,000 retail locations. In addition, the company has developed a new in-house partner-enabled product opportunity, LifeAgain, a set of algorithms and programs to support specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases.

    For additional information, visit www.CardiumTHX.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.